Furthermore, the CM from thalidomide-treated gastric cancer cells displayed an impaired effect to promote the proliferation, migration, and tube formation of HUVECs, indicating that thalidomide may target SALL4 to inhibit VEGF signaling. This evidence concerns the gene SALL4 and gastric cancer.